7037 Clinical, biochemical (PSA) and radiographic benefit with sunitinib as a single agent in metastatic chemoresistant and hormone-refractory prostate cancer (HRPC) patients.

Details

Language :

English

ISSN :

13596349

Volume :

7

Issue :

2

Database :

Supplemental Index

Journal :

EJC Supplements

Publication Type :

Academic Journal

Accession number :

44463513

Full Text :

https://doi.org/10.1016/S1359-6349(09)71415-6